- A phase 2 study of Endo International's ( NASDAQ: ENDP ) collagenase clostridium histolyticum ("CCH") for adhesive capsulitis of the shoulder (frozen shoulder) missed its primary endpoint .
- Shares are down ~10% in premarket trading.
- The difference between the treatment and placebo group based on improvement in the adapted American Shoulder and Elbow Surgeons Standardized Shoulder Form composite score was not statistically significant.
- As a result, Endo ( ENDP ) said it would be "reevaluating our path forward" with respect to CCH.
- Endo ( ENDP ) shares have fluctuated wildly this week, and on Thursday closed down 11% after the company said it would not make a debt interest payment .
For further details see:
Endo 'frozen shoulder' treatment fails in mid-stage study; shares down 10% premarket